Eagle Pharmaceuticals (EGRX) News Today $3.00 +0.11 (+3.63%) As of 07/3/2025 09:30 AM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EGRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period EGRX Eagle Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comEagle Pharmaceuticals Insider Trading Activity | OTC:EGRX | BenzingaApril 28, 2025 | benzinga.comEagle Pharmaceuticals announces $69M pact to monetize Bendeka royaltiesApril 1, 2025 | markets.businessinsider.comEagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® RoyaltiesMarch 31, 2025 | markets.businessinsider.comEagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights PlanMarch 21, 2025 | globenewswire.comEagle Pharmaceuticals to Delist from NasdaqNovember 18, 2024 | investing.comEagle Announces Update on Delisting from Nasdaq and SEC DeregistrationNovember 15, 2024 | globenewswire.comEagle Pharmaceuticals Appoints New CFO Amid Leadership ChangeNovember 12, 2024 | markets.businessinsider.comEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanNovember 1, 2024 | finanznachrichten.deEagle Pharmaceuticals Implements Stockholder Rights PlanNovember 1, 2024 | markets.businessinsider.comEagle Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanOctober 31, 2024 | markets.businessinsider.comUnion Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals SharesOctober 8, 2024 | gurufocus.comEagle Pharmaceuticals (NASDAQ:EGRX) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.com173,365 Shares in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Bought by Perceptive Advisors LLCSeptember 30, 2024 | marketbeat.comEagle Pharmaceuticals IncSeptember 28, 2024 | money.usnews.comEagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.comSeptember 26, 2024 | marketbeat.comIs Eagle Materials Inc. (EXP) the Best Stock Pick You Need to Know in Jim Cramer’s Latest Watchlist?September 15, 2024 | msn.comEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Short Interest UpdateAugust 31, 2024 | marketbeat.comEagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqAugust 27, 2024 | globenewswire.comEagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Crosses Below Two Hundred Day Moving Average of $4.98August 17, 2024 | marketbeat.comEagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.comAugust 17, 2024 | marketbeat.comAcadian Asset Management LLC Sells 235,109 Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)July 29, 2024 | marketbeat.comEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Sees Large Decline in Short InterestJuly 3, 2024 | marketbeat.comEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Sees Significant Decrease in Short InterestJune 18, 2024 | marketbeat.comEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 22, 2024 | finanznachrichten.deEagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 22, 2024 | globenewswire.comBrandes Investment Partners LP Lowers Stock Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)May 21, 2024 | marketbeat.comEagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual MeetingApril 30, 2024 | finance.yahoo.comEagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, FloridaApril 15, 2024 | globenewswire.comEagle Pharmaceuticals faces potential Nasdaq delistingApril 13, 2024 | investing.comStocks Slightly Higher as US Mar PPI Climbs Less Than ExpectedApril 13, 2024 | msn.comStocks Mixed as Bond Yields ClimbApril 13, 2024 | msn.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KApril 12, 2024 | finance.yahoo.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KApril 12, 2024 | globenewswire.comEagle Pharmaceuticals to cut 36% of workforceFebruary 29, 2024 | msn.comEagle Pharmaceuticals Stock (NASDAQ:EGRX), Short Interest ReportFebruary 22, 2024 | benzinga.comEagle Pharmaceuticals Stock (NASDAQ:EGRX) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comBrandes Investment Partners LP Boosts Stock Holdings in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)February 19, 2024 | marketbeat.comEAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their OptionsFebruary 9, 2024 | prnewswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)February 8, 2024 | stockhouse.comLevi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming DeadlineFebruary 8, 2024 | markets.businessinsider.comShareholders that lost money on Eagle Pharmaceuticals, Inc.(EGRX) should contact Levi & Korsinsky about pending Class Action - EGRXFebruary 8, 2024 | markets.businessinsider.comClass Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) Seeking Recovery for Investors - Contact Levi & KorsinskyFebruary 7, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming DeadlineFebruary 6, 2024 | stockhouse.com7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmFebruary 2, 2024 | stockhouse.comEGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm!February 2, 2024 | barrons.comAssenagon Asset Management S.A. Has $3.43 Million Stock Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)February 2, 2024 | marketbeat.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmFebruary 1, 2024 | stockhouse.comEagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Passes Below Two Hundred Day Moving Average of $12.10February 1, 2024 | marketbeat.comEGRX 9-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities...February 1, 2024 | markets.businessinsider.com Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address EGRX Media Mentions By Week EGRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EGRX News Sentiment▼0.000.58▲Average Medical News Sentiment EGRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EGRX Articles This Week▼00▲EGRX Articles Average Week Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CGEN News ALEC News GALT News ACOG News IKT News ALTS News KYTX News RAPT News LXEO News BDTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EGRX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EGRX Stock Alerts